OIPE CO.

PTC/SB08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

or form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Carlos Plata-Salaman
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1453

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.¹		nd Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns Lines, where relevant passages or relevant figures appear
		4,513,006		Maryanoff et al	04/23/1985	
		5,242,942		Costanzo et al	09/07/1993	
		5,387,700		Maryanoff et al	02/07/1995	
		6,071,537		Shank	06/06/2000	
		6,191,163	B1	Cottrell	02/20/2001	
-						
				r.		
				CAIL		
			31	Cr /		
		NV				
		J J	,			
			FÓR	EIGN PATENT DOCUMENTS		

Examiner Initials	Cite	Foreign Office ³	Patent Docu	mept KindCode ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
	No.1	wo	00/61139	A1	Ortho-McNeil Pharmaceutical, Inc.	10/19/2000		
		wg/	00/61140	A1 .	Ortho-McNeil Pharmaceutical, Inc.	10/19/2000		
	ļ —	wo ·	99/44581	A2	Ortho-McNeil Pharmaceutical, Inc.	09/10/1999		
		wo	00/50020	A2	University of Cincinnati	08/31/2000		
		wo	00/76493	A1	Najarian	12/21/2000		
_								

Examiner Signature	Leigh C. Maier	Date Considered	9-8-04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00) Approved for use through 10/31/2001. OMB 0651-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

valid OMB control number.
09/900,567
July 6, 2001
Carlos Plata-Salaman
ORT-1453

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
LCM		OSBORNE et al, Topiramate Improves Glycemic Control and Triglycerides in Animal Models. Presented to ADA. Abstracts published on line http://www.diabetes.org/am01/AnnualMeeting/Abstracts/AbstractSearch.asp pp 1-11 Abstract, June 2001	
LCM		OSBORNE Figures 4 pages DEMAREST, K. ET AL Topiramate Improves Tolerance and May Improve Insulin Sensitivity In Animal Models of Type 2 Diabetes Mellitus. Pages 1-10. Abstract, June 2001	
LCM		DEMARCST POSTER 6 PAGES Figure 1a to Figure 4 CROOKE et al. ABSTRACT, Topiramate Improves Glycemic Control Independent of Weight Loss in ob/ob Mice 1 page, June 2001	
LCM		DEMAREST ET AL ABSTRACT Topiramate Improves Glucose Tolerance and May Improve Insulin Sensitivity in Animal Models of Type 2 Diabetes Mellitus 1 page	
LCM		OSBORNE ET AL ABSTRACT Topiramate Improves Glycemic Control and Triglycendes in Animal Models 1 page, June 2001	

			_
Examiner	Laint C Mai	Date Q 0- 0/	
Signature	Lugh C. Maur	Considered 1-0-04	- 1

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.